CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

Irritable Bowel Syndrome: Taking Concepts Into Clinical Practice CME
Chairperson: Michael D. Gershon, MD; Faculty: Kevin W. Olden, MD; Walter L. Peterson, MD; Nicholas J. Talley, MD, PhD; Gervais Tougas, MD, CM, FRCPC
Disclosures

Release Date: August 15, 2002; Valid for credit through August 15, 2003

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Irritable Bowel Syndrome: Taking Concepts Into Clinical Practice" symposium held at the Palace Hotel in San Francisco, California on May 20, 2002.

Contents of This CME Activity
This program is offered in two formats. Please choose one of the versions:

    Flash Version
    (A multimedia presentation with synchronized audio, slides and transcript.)
    Note: Macromedia's Flash Player 5 plug-in is required to view the Flash version.
    Download the Macromedia Flash Player 5 plug-In:

    Get Flash 5

    --OR--

    Slides with transcript and RealAudio:

  1. The Incidence and Socioeconomic Burden of the Illness
    Epidemiology of Irritable Bowel Syndrome
    Annual Visits to Office-Based Practices
    Utilization of Healthcare Resources by Patients With Irritable Bowel Syndrome
    Negative Impact of Irritable Bowel Syndrome on Quality of Life, Work-Related Issues, and Productivity
    Economic Burden of Irritable Bowel Syndrome: Direct, Indirect, and Intangible Costs
    Summary

  2. Integrating Current Concepts of Causality: Towards a Unifying Hypothesis
    Phenomenology, Pathophysiology, and Symptomatology of Irritable Bowel Syndrome
    Involvement of the Brain-Gut Axis in Central and Visceral Hypersensitivity
    Psychological and Enteric Factors Associated With the Symptoms of Irritable Bowel Syndrome
    Potential Pathogenetic Role of Serotoninergic Mechanisms in the Symptoms of Irritable Bowel Syndrome
    Summary

  3. Current Treatments: Do They Meet the Clinical Need?
    Current Symptomatic Treatments of Irritable Bowel Syndrome
    Effect of High Placebo Response in Irritable Bowel Syndrome Clinical Trials
    Initial Therapeutic Management of Irritable Bowel Syndrome: Education and Reassurance
    Review and Assessment of Treatment Trials in Irritable Bowel Syndrome
    Initial Therapeutic Management of Irritable Bowel Syndrome: Dietary Advice
    Current Pharmacologic Treatment of Irritable Bowel Syndrome: Smooth Muscle Relaxants and Anticholinergics
    Current Pharmacologic Treatment of Irritable Bowel Syndrome: Antidepressants
    Current Pharmacologic Treatment of Irritable Bowel Syndrome: Other Agents
    Current Nonpharmacologic Treatment of Irritable Bowel Syndrome: Psychological Intervention
    Conclusions

  4. An Evidence-Based Approach to the Management of IBS
    Rome Criteria for Clinical Study Methodology
    Study Designs of Tegaserod Phase III Clinical Trials
    Therapeutic Efficacy of Tegaserod Using the Subjective Global Assessment of Symptom Relief
    Meta-Analysis of Randomized Controlled Trials of Tegaserod in Irritable Bowel Syndrome
    Effect of Tegaserod on the Incidence of Abdominal Surgery/Cholecystectomy in Patients With Irritable Bowel Syndrome
    Safety and Tolerability of Tegaserod in Patients With Irritable Bowel Syndrome
    Conclusions

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape, the CME provider, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity.

 
Copyright © 2002 CME Consultants, Inc.
Novartis
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.